Double Historical Income Statement

002901 Stock

32.77 0.37 1.14%

Historical analysis of Double Medical income statement accounts such as Other Operating Expenses of 17.8 M, Net Income Applicable To Common Shares of 443.1 M or Income Tax Expense of 75.9 M can show how well Double Medical Technology performed in making a profits. Evaluating Double Medical income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Double Medical's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Double Medical Technology latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Double Medical Technology is a good buy for the upcoming year.

Net Income Gross Profit

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Double Medical Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Double Income Statement Analysis

Double Medical Technology Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Double Medical shareholders. The income statement also shows Double investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Double Medical Income Statement Chart

At present, Double Medical's Interest Expense is projected to increase significantly based on the last few years of reporting. The current year's Gross Profit is expected to grow to about 1.1 B, whereas Other Operating Expenses is forecasted to decline to about 17.8 M.

Other Operating Expenses Income Tax Expense Tax Provision Selling General Administrative

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Double Medical Technology. It is also known as Double Medical overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Double Medical's income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Double Medical Technology current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Double Medical Technology. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Net Interest Income	13.7M	17.6M	22.4M	16.3M
Tax Provision	111.0M	37.9M	13.4M	12.7M

Net Interest Income Tax Provision

Double Medical income statement Correlations

	Other Operating Expenses	Income Tax Expense	Minority Interest	Tax Provision	Net Interest Income	Interest Income	Selling General Administrative	Total Revenue	Gross Profit	Operating Income	Net Income From Continuing Ops	Ebit	Research Development	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Net Income	Ebitda	Reconciled Depreciation
Other Operating Expenses		0.96	-0.38	0.24	0.81	0.86	0.91	0.9	0.84	0.27	0.23	0.97	0.92	0.94	0.94	0.23	0.19	0.26	0.9
Income Tax Expense	0.96		-0.33	0.3	0.9	0.93	0.96	0.95	0.9	0.31	0.27	0.99	0.93	0.94	0.97	0.27	0.23	0.31	0.91
Minority Interest	-0.38	-0.33		0.52	-0.01	-0.12	-0.39	-0.31	-0.22	0.47	0.5	-0.41	-0.58	-0.57	-0.5	0.51	0.53	0.39	-0.64
Tax Provision	0.24	0.3	0.52		0.36	0.25	0.32	0.45	0.55	0.97	0.98	0.25	-0.04	0.01	0.16	0.98	0.98	0.95	-0.08
Net Interest Income	0.81	0.9	-0.01	0.36		0.99	0.85	0.86	0.84	0.36	0.33	0.85	0.75	0.78	0.82	0.34	0.29	0.35	0.72
Interest Income	0.86	0.93	-0.12	0.25	0.99		0.87	0.86	0.82	0.26	0.22	0.9	0.83	0.85	0.87	0.23	0.18	0.25	0.8
Selling General Administrative	0.91	0.96	-0.39	0.32	0.85	0.87		0.97	0.94	0.31	0.27	0.97	0.91	0.9	0.98	0.28	0.23	0.34	0.9
Total Revenue	0.9	0.95	-0.31	0.45	0.86	0.86	0.97		0.99	0.49	0.44	0.95	0.83	0.86	0.93	0.45	0.4	0.51	0.82
Gross Profit	0.84	0.9	-0.22	0.55	0.84	0.82	0.94	0.99		0.58	0.55	0.89	0.74	0.77	0.87	0.55	0.51	0.6	0.73
Operating Income	0.27	0.31	0.47	0.97	0.36	0.26	0.31	0.49	0.58		1.0	0.27	-0.03	0.05	0.17	1.0	0.99	0.99	-0.06
Net Income From Continuing Ops	0.23	0.27	0.5	0.98	0.33	0.22	0.27	0.44	0.55	1.0		0.23	-0.07	0.01	0.12	1.0	1.0	0.98	-0.11
Ebit	0.97	0.99	-0.41	0.25	0.85	0.9	0.97	0.95	0.89	0.27	0.23		0.95	0.96	0.99	0.23	0.19	0.29	0.94
Research Development	0.92	0.93	-0.58	-0.04	0.75	0.83	0.91	0.83	0.74	-0.03	-0.07	0.95		0.98	0.97	-0.07	-0.12	-0.01	1.0
Cost Of Revenue	0.94	0.94	-0.57	0.01	0.78	0.85	0.9	0.86	0.77	0.05	0.01	0.96	0.98		0.97	0.01	-0.04	0.08	0.98
Total Operating Expenses	0.94	0.97	-0.5	0.16	0.82	0.87	0.98	0.93	0.87	0.17	0.12	0.99	0.97	0.97		0.13	0.08	0.2	0.97
Income Before Tax	0.23	0.27	0.51	0.98	0.34	0.23	0.28	0.45	0.55	1.0	1.0	0.23	-0.07	0.01	0.13		1.0	0.98	-0.1
Net Income	0.19	0.23	0.53	0.98	0.29	0.18	0.23	0.4	0.51	0.99	1.0	0.19	-0.12	-0.04	0.08	1.0		0.98	-0.15
Ebitda	0.26	0.31	0.39	0.95	0.35	0.25	0.34	0.51	0.6	0.99	0.98	0.29	-0.01	0.08	0.2	0.98	0.98		-0.03
Reconciled Depreciation	0.9	0.91	-0.64	-0.08	0.72	0.8	0.9	0.82	0.73	-0.06	-0.11	0.94	1.0	0.98	0.97	-0.1	-0.15	-0.03

Click cells to compare fundamentals

Double Medical Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

TITAN	Titan Company Limited
U	Unity Software
PAYC	Paycom Soft

Other Information on Investing in Double Stock

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Double Historical Income Statement

About Double Income Statement Analysis

Double Medical Income Statement Chart

Other Operating Expenses

Tax Provision

Double Medical income statement Correlations

Double Medical Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Other Information on Investing in Double Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Interest Expense	Other Operating Expenses
Net Income Applicable To Common Shares	Income Tax Expense
Minority Interest	Tax Provision
Net Interest Income	Interest Income
Selling General Administrative	Total Revenue
Gross Profit	Operating Income
Net Income From Continuing Ops	Ebit
Research Development	Cost Of Revenue
Total Operating Expenses	Income Before Tax
Net Income	Ebitda
Reconciled Depreciation

Net Income From Continuing Ops	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Net Income From Continuing Ops
Net Income	+ 1.0	Net Income From Continuing Ops
Reconciled Depreciation	+ 1.0	Research Development
Net Income	+ 1.0	Income Before Tax

Reconciled Depreciation	- 0.64	Minority Interest
Research Development	- 0.58	Minority Interest
Cost Of Revenue	- 0.57	Minority Interest
Total Operating Expenses	- 0.5	Minority Interest
Ebit	- 0.41	Minority Interest
Selling General Administrative	- 0.39	Minority Interest